Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.

Non-AIDS conditions such as cardiovascular disease and non-AIDS defining cancers dominate causes of morbidity and mortality among persons with HIV on suppressive combination antiretroviral therapy. Accurate estimates of disease incidence and of risk factors for these conditions are important in plan...

Full description

Bibliographic Details
Main Authors: Christopher J Miller, Jason V Baker, Alison M Bormann, Kristine M Erlandson, Katherine Huppler Hullsiek, Amy C Justice, Jacqueline Neuhaus, Roger Paredes, Kathy Petoumenos, Deborah Wentworth, Alan Winston, Julian Wolfson, James D Neaton, INSIGHT SMART Study Group, ESPRIT Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3984283?pdf=render
id doaj-22905c7d9a924e4491abe8a56500467f
record_format Article
spelling doaj-22905c7d9a924e4491abe8a56500467f2020-11-25T02:17:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0194e9506110.1371/journal.pone.0095061Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.Christopher J MillerJason V BakerAlison M BormannKristine M ErlandsonKatherine Huppler HullsiekAmy C JusticeJacqueline NeuhausRoger ParedesKathy PetoumenosDeborah WentworthAlan WinstonJulian WolfsonJames D NeatonINSIGHT SMART Study GroupESPRIT Study GroupNon-AIDS conditions such as cardiovascular disease and non-AIDS defining cancers dominate causes of morbidity and mortality among persons with HIV on suppressive combination antiretroviral therapy. Accurate estimates of disease incidence and of risk factors for these conditions are important in planning preventative efforts.With use of medical records, serious non-AIDS events, AIDS events, and causes of death were adjudicated using pre-specified criteria by an Endpoint Review Committee in two large international trials. Rates of serious non-AIDS which include cardiovascular disease, end-stage renal disease, decompensated liver disease, and non-AIDS cancer, and other serious (grade 4) adverse events were determined, overall and by age, over a median follow-up of 4.3 years for 3,570 participants with CD4+ cell count ≥300 cells/mm³ who were taking antiretroviral therapy and had an HIV RNA level ≤500 copies/mL. Cox models were used to examine the effect of age and other baseline factors on risk of a composite outcome of all-cause mortality, AIDS, or serious non-AIDS.Five-year Kaplan-Meier estimates of the composite outcome, overall and by age were 8.3% (overall), 3.6% (<40), 8.7% (40-49) and 16.1% (≥50), respectively (p<0.001). In addition to age, smoking and higher levels of interleukin-6 and D-dimer were significant predictors of the composite outcome. The composite outcome was dominated by serious non-AIDS events (overall 65% of 277 participants with a composite event). Most serious non-AIDS events were due to cardiovascular disease and non-AIDS cancers.To date, few large studies have carefully collected data on serious non-AIDS outcomes. Thus, reliable estimates of event rates are scarce. Data cited here, from a geographically diverse cohort, will be useful for planning studies of interventions aimed at reducing rates of serious non-AIDS events among people with HIV.http://europepmc.org/articles/PMC3984283?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Christopher J Miller
Jason V Baker
Alison M Bormann
Kristine M Erlandson
Katherine Huppler Hullsiek
Amy C Justice
Jacqueline Neuhaus
Roger Paredes
Kathy Petoumenos
Deborah Wentworth
Alan Winston
Julian Wolfson
James D Neaton
INSIGHT SMART Study Group
ESPRIT Study Group
spellingShingle Christopher J Miller
Jason V Baker
Alison M Bormann
Kristine M Erlandson
Katherine Huppler Hullsiek
Amy C Justice
Jacqueline Neuhaus
Roger Paredes
Kathy Petoumenos
Deborah Wentworth
Alan Winston
Julian Wolfson
James D Neaton
INSIGHT SMART Study Group
ESPRIT Study Group
Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.
PLoS ONE
author_facet Christopher J Miller
Jason V Baker
Alison M Bormann
Kristine M Erlandson
Katherine Huppler Hullsiek
Amy C Justice
Jacqueline Neuhaus
Roger Paredes
Kathy Petoumenos
Deborah Wentworth
Alan Winston
Julian Wolfson
James D Neaton
INSIGHT SMART Study Group
ESPRIT Study Group
author_sort Christopher J Miller
title Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.
title_short Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.
title_full Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.
title_fullStr Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.
title_full_unstemmed Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.
title_sort adjudicated morbidity and mortality outcomes by age among individuals with hiv infection on suppressive antiretroviral therapy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Non-AIDS conditions such as cardiovascular disease and non-AIDS defining cancers dominate causes of morbidity and mortality among persons with HIV on suppressive combination antiretroviral therapy. Accurate estimates of disease incidence and of risk factors for these conditions are important in planning preventative efforts.With use of medical records, serious non-AIDS events, AIDS events, and causes of death were adjudicated using pre-specified criteria by an Endpoint Review Committee in two large international trials. Rates of serious non-AIDS which include cardiovascular disease, end-stage renal disease, decompensated liver disease, and non-AIDS cancer, and other serious (grade 4) adverse events were determined, overall and by age, over a median follow-up of 4.3 years for 3,570 participants with CD4+ cell count ≥300 cells/mm³ who were taking antiretroviral therapy and had an HIV RNA level ≤500 copies/mL. Cox models were used to examine the effect of age and other baseline factors on risk of a composite outcome of all-cause mortality, AIDS, or serious non-AIDS.Five-year Kaplan-Meier estimates of the composite outcome, overall and by age were 8.3% (overall), 3.6% (<40), 8.7% (40-49) and 16.1% (≥50), respectively (p<0.001). In addition to age, smoking and higher levels of interleukin-6 and D-dimer were significant predictors of the composite outcome. The composite outcome was dominated by serious non-AIDS events (overall 65% of 277 participants with a composite event). Most serious non-AIDS events were due to cardiovascular disease and non-AIDS cancers.To date, few large studies have carefully collected data on serious non-AIDS outcomes. Thus, reliable estimates of event rates are scarce. Data cited here, from a geographically diverse cohort, will be useful for planning studies of interventions aimed at reducing rates of serious non-AIDS events among people with HIV.
url http://europepmc.org/articles/PMC3984283?pdf=render
work_keys_str_mv AT christopherjmiller adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT jasonvbaker adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT alisonmbormann adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT kristinemerlandson adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT katherinehupplerhullsiek adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT amycjustice adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT jacquelineneuhaus adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT rogerparedes adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT kathypetoumenos adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT deborahwentworth adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT alanwinston adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT julianwolfson adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT jamesdneaton adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT insightsmartstudygroup adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
AT espritstudygroup adjudicatedmorbidityandmortalityoutcomesbyageamongindividualswithhivinfectiononsuppressiveantiretroviraltherapy
_version_ 1724884124548726784